| Article Access Statistics|
| Viewed||709 |
| Printed||16 |
| Emailed||0 |
| PDF Downloaded||38 |
| Comments ||[Add] |
Click on image for details.
|Year : 2019 | Volume
| Issue : 6 | Page : 1491
Stem Cell Therapy for Ischemic Stroke Injury: A Current Status
Senior Scientist, Roswell Biotechnologies Professional Collaborator, The Scripps Research Institute, La Jolla, CA, USA
|Date of Web Publication||20-Dec-2019|
Dr. Pius Padayatti
Senior Scientist, Roswell Biotechnologies Professional Collaborator, The Scripps Research Institute, La Jolla, CA
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Padayatti P. Stem Cell Therapy for Ischemic Stroke Injury: A Current Status. Neurol India 2019;67:1491
According to the World Health Organization, fifteen million people die of ischemic stroke worldwide each year. The brain is an organ that has no capability to regenerate, unlike many other organs of our body. An injury to this organ normally till date remains untreatable to conditions with no return. A traumatic brain injury (TBI) triggers a reparative process identified as release of a set of molecules called damage-associated molecular patterns (DAMPs). The effort by our body to repair the damage is natural, yet when the injury is larger than the normal repair abilities, an inflammatory response ensues that leads to neurodegeneration and thus permanent damage. Stem cells are undifferentiated cell types that have the potential to populate to form cells like themselves and differentiate into various types of cells under various hormonal influences. Various thermally controlled immortalised neuronal progenitors such as RMNE6 have been developed and show high promise in ischemic therapy. Systematic studies leading to effective implementation of these new approaches are a very exciting development.
The challenges in the TBI field is one of the toughest problems for stem cell research. Some different types of stem cells such as embryonic stem cells (ESCs), multipotent adult progenitor cells (MPCs), adult neural stem cells (NSCs), and inducible pluripotent stem cells (iPSCs) have been developed. Mesenchymal stem cells (MSCs) and bone marrow stromal cells (BMSCs) are various exogenous stem cell types. The promises of these developments in the TBI field are very encouraging. More work in this direction where cell lines with features suited for proliferation without a tumor-like formation are anticipated.
In this volume, the study by Wu et al. makes a comparative study of two such stem cells in a very systematic way. The study is a follow-up of similar studies previously published  with more extensive analytical tools to see the extent of stem cell-mediated repair process in focal ischemia models.
| » References|| |
Wu Y, Yang LW, Zhai XY, Liu JC. Comparison of intracerebral transplantation of RMNE6 cells and MSCs on ischemic stroke models. Neurol India 2019;67:1482-90. [Full text]
World health report 2002. Reducing risks, promoting healthy life. Geneva, World Health Organization, 2002.
Reis C, Gospodarev V, Reis H, Wilkinson M, Gaio J, Araujo C, et al
. Traumatic brain injury and stem cell: pathophysiology and update on recent treatment modalities. Stem Cells Int 2017;2017:13. Article ID 6392592.
Wu Y, Wu J, Ju R, Chen Z, Xu Q. Comparison of intracerebral transplantation effects of different stem cells on rodent stroke models. Cell Biochem Funct 2015;33:174-82.